Childhood Asthma in Urban Settings Clinical Research Network - Leadership Center
Project Number5UM1AI160040-04
Contact PI/Project LeaderJACKSON, DANIEL J Other PIs
Awardee OrganizationUNIVERSITY OF WISCONSIN-MADISON
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
The overall goals of our Childhood Asthma in Urban Settings (CAUSE)-Leadership Center proposal are to
provide administrative leadership and support to develop and conduct collaborative research to address high
priority unmet needs for childhood asthma in urban communities, including: a) developing strategies to prevent
asthma, b) improving treatment and inhibiting progression, c) reducing severe exacerbations, and d) defining
endotypes of respiratory health and disease. Four hypotheses are proposed to accomplish these goals. First,
supplementation with immune modulating bacteria in infancy will prevent the early life perturbations in the gut
microbiome that have been associated with risk for the development of allergic sensitization and asthma, and
will promote airway mucosal immune development. Second, given the importance of cockroach (CR) allergy
and exposure to asthma morbidity in urban children, CR immunotherapy will improve asthma control and
reduce disease progression. Third, we propose that transcriptional analysis of airway cells will define T2-low
mechanisms that contribute to both non-atopic and atopic asthma and provide new insights into treatment.
Finally, multi-omics evaluation of airway cells and secretions obtained during severe exacerbations leading to
ED visits and hospitalizations will reveal novel mechanistic pathways to inform improved treatment and
prevention. We propose five protocols to test these hypotheses:
1. Urban Environment and Childhood Asthma study (URECA)
2. Effects of a Microbial Supplement (STMC-103H) on Microbial Colonization and Immune Development
3. Cockroach (CR) Immunotherapy (IT) in Urban Children with Moderate-Severe Asthma Protected by
Omalizumab
4. Pathogenesis and Mechanisms of T2-low (Non-Atopic) Asthma
5. Severe Asthma Exacerbations in the Emergency Department (ED) and Hospital: Identifying Targets for
Prevention and Treatment
It is our expectation that our proposed CAUSE research program will provide critical information needed to
recognize asthma phenotypes and endotypes in urban children, improve treatment of asthma and establish
direction for prevention. Collectively, these studies will continue the rigorous programmatic approach of the
NIAID Asthma Networks towards achieving the long-term goals of disease modification and prevention of
disease in high-risk children of low-income families living in urban communities.
Public Health Relevance Statement
PROJECT NARRATIVE
Asthma disproportionately affects children in urban communities in the United States and imposes a great
personal and health care burden. Despite treatment advances, a significant proportion of patients do not
achieve disease control and continue to have high levels of morbidity and currently no intervention has proven
to either prevent or cure this disease. By identifying and addressing these unmet needs in this application, we
propose to improve current asthma care in urban children, pursue disease modification, and ultimately develop
effective strategies to prevent asthma.
NIH Spending Category
No NIH Spending Category available.
Project Terms
17 year oldAccident and Emergency departmentAddressAffectAirAllergensAllergicAsthmaBacteriaBirthCaringCellsChildChildhood AsthmaClinical ResearchClinical TrialsDevelopmentDictyopteraDietary InterventionDiseaseDisease ProgressionDouble-Blind MethodEmergency department visitEnrollmentEnvironmental Risk FactorEvaluationEventExposure toExtrinsic asthmaFamily history ofGenetic TranscriptionGoalsGuidelinesHospitalizationHospitalsHypersensitivityImmuneImmunotherapyInfantInfection preventionInflammationInterventionIntervention TrialLeadershipLifeMicrobeModificationMolecularMorbidity - disease rateNational Institute of Allergy and Infectious DiseaseObservational StudyOutpatientsPathogenesisPathway interactionsPatientsPatternPhasePhenotypePlacebo ControlPollutionPreventionProtocols documentationRecurrenceResearchRespiratory DiseaseRespiratory MucosaRhinitisRiskRisk FactorsRoleSelf CareSeveritiesStressSupplementationTestingUnited StatesUrban CommunityVisionWheezingairway immune responseasthma exacerbationcommon treatmentdisorder controldisorder preventiondouble-blind placebo controlled trialeffective therapyexpectationgut microbiomehealthcare burdenhigh riskimmunoregulationimprovedinfancyinsightlongitudinal analysislower income familiesmicrobialmicrobial colonizationmicrobiomemultiple omicsnovelnovel strategiesomalizumabpreventprogramsrespiratory healthsubcutaneousurban childrenurban setting
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
161202122
UEI
LCLSJAGTNZQ7
Project Start Date
12-April-2021
Project End Date
31-March-2028
Budget Start Date
01-April-2024
Budget End Date
31-March-2025
Project Funding Information for 2024
Total Funding
$6,284,859
Direct Costs
$5,854,164
Indirect Costs
$430,695
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$6,284,859
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5UM1AI160040-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5UM1AI160040-04
Patents
No Patents information available for 5UM1AI160040-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5UM1AI160040-04
Clinical Studies
No Clinical Studies information available for 5UM1AI160040-04
News and More
Related News Releases
No news release information available for 5UM1AI160040-04
History
No Historical information available for 5UM1AI160040-04
Similar Projects
No Similar Projects information available for 5UM1AI160040-04